Literature DB >> 23987739

Challenging and complex decisions in the management of the BRCA mutation carrier.

Daniela L Stan1, Lynne T Shuster, Myra J Wick, Casey L Swanson, Sandhya Pruthi, Jamie N Bakkum-Gamez.   

Abstract

Women afflicted by the hereditary breast and ovarian cancer syndrome face complex decisions regarding medical interventions aimed at reducing their risk of ovarian and breast cancer, interventions which in turn may interfere with their fertility and cause early menopause. This review addresses selected topics of importance and controversy in the management of the BRCA mutation carrier, such as psychological well-being and quality of life, breast and ovarian cancer screening, risk-reducing interventions for breast cancer and ovarian cancer, the issue of hysterectomy at the time of the risk-reducing salpingo-oophorectomy, health consequences of early surgical menopause, and safety of hormonal therapy after oophorectomy. The information presented is based on an extensive review of the literature on the selected topics and on the expertise of our multidisciplinary team.

Entities:  

Mesh:

Year:  2013        PMID: 23987739      PMCID: PMC4047843          DOI: 10.1089/jwh.2013.4407

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  107 in total

1.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.

Authors:  V McGuire; A Felberg; M Mills; K L Ostrow; R DiCioccio; E M John; D W West; A S Whittemore
Journal:  Am J Epidemiol       Date:  2004-10-01       Impact factor: 4.897

2.  Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer.

Authors:  H L Judd; W E Lucas; S S Yen
Journal:  Am J Obstet Gynecol       Date:  1974-03-15       Impact factor: 8.661

3.  Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

Authors:  I Jacobs; A P Davies; J Bridges; I Stabile; T Fay; A Lower; J G Grudzinskas; D Oram
Journal:  BMJ       Date:  1993-04-17

4.  Concurrent hysterectomy at bilateral salpingo-oophorectomy: benefits, risks, and costs.

Authors:  C M Grover; M Kuppermann; J G Kahn; A E Washington
Journal:  Obstet Gynecol       Date:  1996-12       Impact factor: 7.661

5.  Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.

Authors:  N Einhorn; K Sjövall; R C Knapp; P Hall; R E Scully; R C Bast; V R Zurawski
Journal:  Obstet Gynecol       Date:  1992-07       Impact factor: 7.661

6.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

Review 7.  A review of laparoscopic ureteral injury in pelvic surgery.

Authors:  Adam Ostrzenski; Bartholomew Radolinski; Katarzyna M Ostrzenska
Journal:  Obstet Gynecol Surv       Date:  2003-12       Impact factor: 2.347

8.  The genetic attributable risk of breast and ovarian cancer.

Authors:  E B Claus; J M Schildkraut; W D Thompson; N J Risch
Journal:  Cancer       Date:  1996-06-01       Impact factor: 6.860

9.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

10.  Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

Authors:  Katrina Armstrong; J Sanford Schwartz; Thomas Randall; Stephen C Rubin; Barbara Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  19 in total

Review 1. 

Authors:  Ruth Heisey; June C Carroll
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

Review 2.  Identification and management of women with a family history of breast cancer: Practical guide for clinicians.

Authors:  Ruth Heisey; June C Carroll
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

3.  Communication is the key. : Part 2 : Direct to consumer genetics in our future daily life ?

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2014-11-19       Impact factor: 5.782

4.  Walking in the shoes of patients, not just in their genes: a patient-centered approach to genomic medicine.

Authors:  Neeraj K Arora; Bradford W Hesse; Steven B Clauser
Journal:  Patient       Date:  2015-06       Impact factor: 3.883

5.  Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.

Authors:  Terri Jabaley; Meghan L Underhill-Blazey; Donna L Berry
Journal:  J Cancer Educ       Date:  2020-04       Impact factor: 2.037

Review 6.  Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

Authors:  Lisa Jeffers; Joanne Reid; Donna Fitzsimons; Patrick J Morrison; Martin Dempster
Journal:  Cochrane Database Syst Rev       Date:  2019-10-09

7.  Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.

Authors:  Ian Solsky; Jinbo Chen; Timothy R Rebbeck
Journal:  Gynecol Oncol       Date:  2020-01-07       Impact factor: 5.304

Review 8.  BRCA-associated ovarian cancer: from molecular genetics to risk management.

Authors:  Giulia Girolimetti; Anna Myriam Perrone; Donatella Santini; Elena Barbieri; Flora Guerra; Simona Ferrari; Claudio Zamagni; Pierandrea De Iaco; Giuseppe Gasparre; Daniela Turchetti
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

Review 9.  Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.

Authors:  Anders W Ohman; Noor Hasan; Daniela M Dinulescu
Journal:  Front Oncol       Date:  2014-11-18       Impact factor: 6.244

Review 10.  Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.

Authors:  Katherine Karakasis; Julia V Burnier; Valerie Bowering; Amit M Oza; Stephanie Lheureux
Journal:  Front Oncol       Date:  2016-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.